trial

NAPLS Omega-3 Fatty Acid Versus Placebo Study

NCTId NCT01429454
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 127 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2016-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
127 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2011-08
Primary completion
2016-06
Eligibility
ALL · 12 Years · 30 Years

Interventions & indications

Drugs
Omega-3 Long Chain Fatty Acid

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Kristin S Cadenhead, MDPrincipal Investigator

Sites

9 total
Los Angeles, United StatesSan Diego, United StatesNew Haven, United StatesAtlanta, United StatesBoston, United StatesGlen Oaks, United StatesChapel Hill, United StatesPittsburgh, United StatesCalgary, Canada

Facts & assertions

4 sourced
Enrollment
127
Phase
PHASE1
Primary Completion Date
2016-06
Status
COMPLETED
relationships
The graph out of here
drug
Omega-3 Long Chain Fatty Acid
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Psychosis
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Kristin S Cadenhead, MD
person